Shares of Gilead Sciences ( GILD 7.46%) were jumping 7.9% higher on Wednesday at 11:34 a.m. The solid gain came after the big ...

Operator Good afternoon, everyone, and welcome to Gilead's fourth quarter and full year 2024 earnings conference call. My ...

FOSTER CITY, Calif. - Gilead Sciences, Inc. (NASDAQ:GILD), a biopharmaceutical firm with a market capitalization of $119.87 billion, announced today a 2.6% increase in its quarterly cash dividend.

Biopharmaceutical company Gilead Sciences (NASDAQ:GILD) will be announcing earnings results tomorrow afternoon. Here’s what ...

Gilead Sciences reported strong fourth-quarter earnings with significant growth in its HIV and oncology segments.

Gilead Sciences is rated a Strong Buy due to strong Q4 2024 results and a robust HIV franchise. Check out my 12-month price ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

In a report released today, Matthew Biegler from Oppenheimer reiterated a Buy rating on Gilead Sciences (GILD – Research Report), with a price ...

Piper Sandler analyst Joseph Catanzaro maintained a Buy rating on Gilead Sciences (GILD – Research Report) today and set a price target of ...

Cindy Perettie; Executive Vice President of Kite; Gilead Sciences Inc. Geoffrey Meacham; Analyst; Citi. Terence Flynn; Analyst; Morgan Stanley. Timothy Anderson; Analyst; BofA Glo ...

Gilead Sciences, Inc. ( NASDAQ: GILD) Q4 2024 Earnings Conference Call February 11, 2025 4:30 PM ET Jacquie Ross - SVP, Treasury & IR Daniel O'Day - Chairman, CEO Johanna Mercier - Chief Commercial ...